Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
CBR Division, Defence Science and Technology Laboratory, Porton Down, Salisbury, UK.
Clin Microbiol Infect. 2020 Sep;26(9):1254.e1-1254.e8. doi: 10.1016/j.cmi.2019.07.028. Epub 2019 Aug 9.
Burkholderia pseudomallei, Yersinia pestis and Francisella tularensis are facultative intracellular bacteria causing life-threatening infections. We have (a) compared the activity of finafloxacin (a fluoroquinolone in development showing improved activity at acidic pH) with that of ciprofloxacin, levofloxacin and imipenem against the extracellular and intracellular (THP-1 monocytes) forms of infection by attenuated surrogates of these species (B. thailandensis, Y. pseudotuberculosis, F. philomiragia) and (b) assessed finafloxacin cellular pharmacokinetics (accumulation, distribution, efflux).
Bacteria in broth or in infected monocytes were exposed to antibiotics at pH 7.4 or 5.5 for 24 hr. Maximal relative efficacies (E) and static concentrations (C) were calculated using the Hill equation (concentration-response curves). Finafloxacin pharmacokinetics in cells at pH 7.4 or 5.5 was investigated using C-labelled drug.
Extracellularly, all drugs sterilized the cultures, with finafloxacin being two to six times more potent at acidic pH. Intracellularly, E reached the limit of detection (4-5 log cfu decrease) for finafloxacin against all species, but only against B. thailandensis and F. philomiragia for ciprofloxacin and levofloxacin, while imipenem caused less than 2 log cfu decrease for all species. At acid pH, C shifted to two to five times lower values for finafloxacin and to one to four times higher values for the other drugs. Finafloxacin accumulated in THP-1 cells by approximately fivefold at pH 7.4 but up to 20-fold at pH 5.5, and distributed in the cytosol.
Fluoroquinolones have proven to be effective in reducing the intracellular reservoirs of B. thailandensis, Y. pseudotuberculosis and F. philomiragia, with finafloxacin demonstrating an additional advantage in acidic environments.
伯克霍尔德氏菌、鼠疫耶尔森菌和土拉弗朗西斯菌是兼性细胞内细菌,可引起危及生命的感染。我们(a)比较了法氟沙星(一种正在开发的氟喹诺酮类药物,在酸性 pH 值下显示出改善的活性)与环丙沙星、左氧氟沙星和亚胺培南对这些物种的减毒替代物(B. thailandensis、Y. pseudotuberculosis、F. philomiragia)的细胞外和细胞内(THP-1 单核细胞)形式感染的活性,以及(b)评估了法氟沙星的细胞药代动力学(积累、分布、外排)。
在 pH 7.4 或 5.5 下,将肉汤中的细菌或感染的单核细胞暴露于抗生素 24 小时。使用 Hill 方程(浓度-反应曲线)计算最大相对效力(E)和静态浓度(C)。使用 C 标记的药物研究了 pH 7.4 或 5.5 时法氟沙星在细胞中的药代动力学。
在细胞外,所有药物均使培养物无菌,法氟沙星在酸性 pH 值下的效力是其他药物的两倍至六倍。在细胞内,E 达到了法氟沙星对所有物种的检测极限(减少 4-5 个对数 CFU),但仅对 B. thailandensis 和 F. philomiragia 的环丙沙星和左氧氟沙星,而亚胺培南对所有物种的减少量不到 2 个对数 CFU。在酸性 pH 值下,C 值降低到法氟沙星的两倍至五倍,而其他药物的值升高到一到四倍。法氟沙星在 pH 7.4 时在 THP-1 细胞中积累约五倍,但在 pH 5.5 时积累高达 20 倍,并分布在细胞质中。
氟喹诺酮类药物已被证明可有效减少 B. thailandensis、Y. pseudotuberculosis 和 F. philomiragia 的细胞内储存,法氟沙星在酸性环境中具有额外优势。